Literature DB >> 20660539

Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency.

Thomas Köhnlein1, Sabina Janciauskiene, Tobias Welte.   

Abstract

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is one of the most prevalent inherited diseases in Whites, but identification of affected patients and establishment of the diagnosis is still unsatisfactory. This study assessed the latencies and numbers of physicians involved in identifying AATD patients, and the importance of smoking, vaccination status, and specific augmentation therapy on the course of the disease.
METHOD: Patients from Germany and Austria underwent a single written interview with 28 items. Five hundred and ninety-six patients were addressed and 44.9% replied.
RESULTS: The age at symptom onset was 39.1±10.1 years, and the diagnosis was established at the age of 45.1±10.9 years. From the 6-year delay in establishing the diagnosis, 1.4±1.7 (range 0.5-10.5) years were due to patients' reluctance to seek medical attention. There were 3.2±2.4 (range 1-13) physicians involved in establishing the diagnosis. Smoking was associated with an earlier onset of respiratory symptoms and lower exercise capacity. Vaccination against pneumococci and/or influenza, and augmentation therapy resulted in significantly fewer exacerbations and fewer emergency room visits. Airway infections and passive smoking during childhood were not found to influence the onset of respiratory symptoms.
CONCLUSIONS: In conclusion, there is still a large delay between symptom onset and AATD diagnosis. Smoking history, vaccination status, and augmentation therapy have an important impact on the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660539     DOI: 10.1177/1753465810376407

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  16 in total

1.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

2.  Designing Clinical Trials in "Regular" COPD Versus Alpha-1 Antitrypsin Deficiency-Associated COPD: "More Alike Than Unalike?"

Authors:  James K Stoller
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

Review 3.  Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.

Authors:  Timm Greulich; Claus F Vogelmeier
Journal:  Ther Adv Respir Dis       Date:  2015-09-04       Impact factor: 4.031

4.  How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?

Authors:  Ilaria Ferrarotti; Beata Poplawska-Wisniewska; Maria Teresa Trevisan; Janine Koepke; Marc Dresel; Rembert Koczulla; Stefania Ottaviani; Raffaele Baldo; Marina Gorrini; Giorgia Sala; Luana Cavallon; Tobias Welte; Joanna Chorostowska-Wynimko; Maurizio Luisetti; Sabina Janciauskiene
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

5.  Diagnosis of alpha-1 antitrypsin deficiency: a population-based study.

Authors:  Miriam Barrecheguren; Mónica Monteagudo; Pere Simonet; Carl Llor; Esther Rodriguez; Jaume Ferrer; Cristina Esquinas; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-10

6.  Selected metabolic aspects of elastin and collagen fiber proteolysis in diseases of the respiratory system - the significance of α1 antitrypsin deficiency.

Authors:  Agata Dżeljilji; Wojciech Rokicki; Krzysztof Karuś
Journal:  Kardiochir Torakochirurgia Pol       Date:  2016-09-30

Review 7.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

Review 8.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

Review 9.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

10.  Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015.

Authors:  Timm Greulich; Christoph Nell; Christian Herr; Claus Vogelmeier; Viktor Kotke; Stefan Wiedmann; Marion Wencker; Robert Bals; Andreas Rembert Koczulla
Journal:  Orphanet J Rare Dis       Date:  2016-06-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.